Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THC and CBD drops in Crohn's disease
NCT01826188Phase 2Completed
- Sponsor
- Meir Medical Center
- Start
- Mar 2013
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing THC/CBD Arm with Placebo Arm (2 arms). Primary endpoint: Crohn's Disease Activity Index decrease of 100 points at 8 weeks. Started Mar 2013; status: completed.
02
Drugs
dronabinolcannabidiol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01826188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01826188.